Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 17 | 2024 | 4958 | 1.580 |
Why?
|
| Glioma | 14 | 2024 | 1978 | 1.410 |
Why?
|
| Cerebellar Neoplasms | 7 | 2022 | 478 | 1.380 |
Why?
|
| Medulloblastoma | 8 | 2021 | 572 | 1.360 |
Why?
|
| Brain Stem Neoplasms | 4 | 2020 | 100 | 1.120 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2018 | 32 | 1.100 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2022 | 551 | 0.910 |
Why?
|
| Astrocytoma | 2 | 2021 | 326 | 0.710 |
Why?
|
| Neuroectodermal Tumors | 2 | 2020 | 33 | 0.710 |
Why?
|
| Fat Necrosis | 1 | 2019 | 60 | 0.660 |
Why?
|
| Anaphylaxis | 1 | 2020 | 123 | 0.660 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 161 | 0.640 |
Why?
|
| Ganglioglioma | 1 | 2018 | 40 | 0.610 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 1437 | 0.590 |
Why?
|
| Needs Assessment | 1 | 2018 | 238 | 0.540 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 232 | 0.540 |
Why?
|
| Rhabdoid Tumor | 2 | 2015 | 106 | 0.540 |
Why?
|
| Ubiquitin | 1 | 2017 | 331 | 0.520 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 1335 | 0.510 |
Why?
|
| Carcinoma | 2 | 2018 | 2609 | 0.490 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 592 | 0.480 |
Why?
|
| Chemoradiotherapy | 4 | 2018 | 2027 | 0.460 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1387 | 0.440 |
Why?
|
| Consolidation Chemotherapy | 1 | 2013 | 153 | 0.420 |
Why?
|
| Neuroblastoma | 1 | 2018 | 705 | 0.410 |
Why?
|
| Child, Preschool | 16 | 2024 | 17048 | 0.410 |
Why?
|
| Ependymoma | 3 | 2020 | 265 | 0.390 |
Why?
|
| Child | 26 | 2024 | 30546 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2399 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 10385 | 0.350 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 670 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 16669 | 0.330 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 916 | 0.310 |
Why?
|
| Prognosis | 11 | 2024 | 22481 | 0.310 |
Why?
|
| Histones | 4 | 2024 | 1512 | 0.270 |
Why?
|
| Infant | 8 | 2021 | 13989 | 0.260 |
Why?
|
| Vincristine | 3 | 2020 | 1582 | 0.260 |
Why?
|
| DNA Methylation | 1 | 2016 | 2767 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 4961 | 0.240 |
Why?
|
| Survival Rate | 6 | 2019 | 12527 | 0.230 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 965 | 0.230 |
Why?
|
| Humans | 38 | 2024 | 270802 | 0.230 |
Why?
|
| Everolimus | 2 | 2023 | 436 | 0.220 |
Why?
|
| Adolescent | 13 | 2024 | 32743 | 0.220 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 9039 | 0.210 |
Why?
|
| Mutation | 7 | 2024 | 15911 | 0.210 |
Why?
|
| Glioblastoma | 2 | 2023 | 1776 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 7895 | 0.200 |
Why?
|
| Infusions, Intraventricular | 2 | 2020 | 28 | 0.200 |
Why?
|
| Ganglioneuroma | 1 | 2020 | 44 | 0.180 |
Why?
|
| Fourth Ventricle | 2 | 2017 | 50 | 0.180 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 105 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 15212 | 0.180 |
Why?
|
| Hydrocephalus | 1 | 2022 | 260 | 0.180 |
Why?
|
| Female | 20 | 2024 | 148967 | 0.170 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 195 | 0.170 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 347 | 0.170 |
Why?
|
| Young Adult | 10 | 2023 | 22225 | 0.170 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2019 | 67 | 0.170 |
Why?
|
| Infant, Newborn | 4 | 2021 | 8699 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 126 | 0.160 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 139 | 0.150 |
Why?
|
| Review Literature as Topic | 1 | 2018 | 84 | 0.150 |
Why?
|
| Pineal Gland | 1 | 2017 | 43 | 0.150 |
Why?
|
| Infratentorial Neoplasms | 1 | 2017 | 48 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 127 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2019 | 352 | 0.140 |
Why?
|
| Male | 14 | 2024 | 128397 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10706 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 894 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 341 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 7017 | 0.120 |
Why?
|
| International Agencies | 1 | 2015 | 108 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2015 | 76 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1470 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2014 | 52 | 0.120 |
Why?
|
| Middle Cerebellar Peduncle | 1 | 2014 | 4 | 0.120 |
Why?
|
| Pons | 1 | 2014 | 54 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 1564 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1189 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 10260 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 322 | 0.110 |
Why?
|
| Adult | 8 | 2023 | 81997 | 0.110 |
Why?
|
| Etoposide | 1 | 2015 | 907 | 0.100 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 14616 | 0.100 |
Why?
|
| Proton Therapy | 1 | 2022 | 1635 | 0.100 |
Why?
|
| Methotrexate | 1 | 2015 | 1025 | 0.100 |
Why?
|
| Carboplatin | 1 | 2015 | 880 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 292 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2013 | 502 | 0.090 |
Why?
|
| Camptothecin | 1 | 2013 | 540 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 39832 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2573 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1366 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 14012 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 661 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2013 | 967 | 0.080 |
Why?
|
| Radiography | 1 | 2013 | 1988 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 6255 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 633 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 2045 | 0.080 |
Why?
|
| Animals | 6 | 2020 | 62048 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 2496 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3243 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1857 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 13417 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2453 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5403 | 0.060 |
Why?
|
| Genomics | 1 | 2014 | 2836 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2161 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 5060 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 3408 | 0.050 |
Why?
|
| Brain Stem | 1 | 2022 | 185 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 2634 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2902 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 1320 | 0.050 |
Why?
|
| Thalamus | 1 | 2021 | 123 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2014 | 3557 | 0.040 |
Why?
|
| Protons | 1 | 2022 | 482 | 0.040 |
Why?
|
| Pyrimidines | 2 | 2024 | 3667 | 0.040 |
Why?
|
| Sirolimus | 1 | 2023 | 831 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 956 | 0.040 |
Why?
|
| Lysine | 1 | 2020 | 426 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 3532 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 364 | 0.040 |
Why?
|
| Piperidines | 1 | 2023 | 1098 | 0.040 |
Why?
|
| Disease Progression | 2 | 2022 | 6855 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2017 | 452 | 0.040 |
Why?
|
| Neoplasms | 1 | 2023 | 15919 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 1579 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 897 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 33741 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 5071 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 12102 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1825 | 0.030 |
Why?
|
| Chromatin | 1 | 2020 | 1046 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 4001 | 0.030 |
Why?
|
| Anisotropy | 1 | 2014 | 181 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1064 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 1442 | 0.030 |
Why?
|
| Pyridines | 1 | 2019 | 1311 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 720 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2376 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5759 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 1499 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 5310 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 5828 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 824 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3919 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6516 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 4213 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 1473 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2848 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 1144 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 35597 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3588 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3845 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3604 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 7237 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1960 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 7754 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 17900 | 0.010 |
Why?
|